TCT-20: Drug-eluting devices in femoropopliteal disease: trends of use and patient outcomesJournal of the American College of Cardiology
Presentation NotesOral presentation at: Transcatheter Cardiovascular Therapuetics; October 29- November 2, 2016; Washington, D.C.
AbstractBACKGROUND: The trends of use and efficacy of drug-coated balloons (DCB) and drug-eluting stents (DES) for femoropopliteal lesions in real-world population remain unclear. METHODS: A retrospective single center study included 301 consecutive lesions successful treated with either DES (51.1%) or DCB (48.9%) between 10/2013 and 2/2015. RESULTS: DES- and DCB-treated groups had a similar number of females (42.2% vs 45.5%, p¼0.56) and patients with diabetes (58.2% vs 67.8%, p¼0.08), renal disease (29.9% vs 34.6%, p¼ 0.4), hypertension (92.8% vs 94.5%, p¼ 0.5) and BMI >30 (43.5% vs 36.7%, B8 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, VOL. 68, NO. 18, SUPPL B, 2016 p¼0.23). The DES-treated group was older (69.1 +/- 11.2 years vs 68.9 +/- 13.2 years, p¼ 0.045) and had more patients with prior or active smoking history (81.7% vs 52.7%, p <0.001). Lesion and procedural characteristics are presented in the table. Freedom from target lesion revascularization (TLR) to one year was similar between treatment groups (figure) despite a 3.2% stent thrombosis rate in the DES-treated group. CONCLUSION: Overall results show similar TVR- free survival at 1 year with a trend toward better TVR in DCB-treated lesions. Stent thrombosis may account for early increase in TLR in DES-treated lesions.
Ortiz D, Kostopoulos L, Nfor T, Allaqaband SQ, Bajwa T. TCT-20: Drug-eluting devices in femoropopliteal disease: trends of use and patient outcomes. J Am Coll Cardiol. 2016;68(18S):B8-9.